Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

10.90 +1.35 (+14.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
MacroGenics To Surge 138%? Plus This Analyst Sees $50 For Exact Sciences
BMO Capital boosted the price target on MacroGenics, Inc. (NASDAQ: MGNX) from $5.7 to $16. BMO Capital analyst Etzer Darout upgraded the stock from Market Perform to Outperform. MacroGenics shares... 
Via Benzinga
RAPT Therapeutics Reports Third Quarter 2022 Financial Results
Company maintains strong cash position of $195.4 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Expert Ratings For RAPT Therapeutics
  RAPT Therapeutics (NASDAQ:RAPT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Recap: RAPT Therapeutics Q2 Earnings
  RAPT Therapeutics (NASDAQ:RAPT) reported its Q2 earnings results on Thursday, August 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Gainers 
Via Benzinga
This Mid-Cap Firm Can Potentially Offer Biggest Oral Drug In Atopic Dermatitis, Cantor Thinks So
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) shares moved upwards by 20.1% to $1.79 during Wednesday's after-market session. The market value of their outstanding shares is at $31.6 million. 
Via Benzinga
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session
Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year. 
Via Benzinga
Recap: RAPT Therapeutics Q1 Earnings
RAPT Therapeutics (NASDAQ:RAPT) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. 
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for RAPT Therapeutics: Here's What You Need To Know
  HC Wainwright & Co. has decided to maintain its Buy rating of RAPT Therapeutics (NASDAQ:RAPT) and raise its price target from $50.00 to $53.00. Shares of RAPT Therapeutics are trading up 14.98% over... 
Via Benzinga
LegalZoom.com, Toast And Some Other Big Stocks Moving Higher On Friday
  WeTrade Group, Inc. (NASDAQ: WETG) jumped 46% to $20.56 after the company announced it entered into a sales agreement with Parkway Medical Limited to sell monkeypox virus test kits and antigen tests... 
Via Benzinga
What 4 Analyst Ratings Have To Say About RAPT Therapeutics
Analysts have provided the following ratings for RAPT Therapeutics (NASDAQ:RAPT) within the last quarter: 
Via Benzinga
Starbucks And 2 Other Stocks Insiders Are Buying
Although the Dow Jones jumped by more than 400 points on Friday, there were a few notable insider trades. 
Via Benzinga
RAPT Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q4, RAPT Therapeutics (NASDAQ:RAPT) posted sales of $756.00 thousand. Earnings were up 3.87%, but RAPT Therapeutics still reported an... 
Via Benzinga
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11,... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows. 
Via Benzinga
RAPT Therapeutics: Q4 Earnings Insights
RAPT Therapeutics (NASDAQ:RAPT) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
65 Biggest Movers From Yesterday
Gainers Brickell Biotech, Inc. (NASDAQ: BBI) shares jumped 58.6% to settle at $0.33 on Tuesday after HC Wainwright & Co initiated coverage on the stock with a Buy rating and... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company... 
Via Benzinga
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: 
Via Benzinga
How Good Are RAPT Therapeutics's Earnings? | Return On Capital Employed
According to Benzinga Pro data, during Q2, RAPT Therapeutics (NASDAQ:RAPT) posted sales of $869.00 thousand. Earnings were up 2.9%, but RAPT Therapeutics still reported an overall... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2021
Upgrades According to Northland Capital Markets, the prior rating for Points International Ltd 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Wedbush boosted Microsoft Corporation (NASDAQ: MSFT) price target from $310 to $325. Microsoft shares slipped 0.1% to $265.48 in pre-market trading. Morgan Stanley boosted... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2021
Upgrades B of A Securities upgraded the previous rating for Cimarex Energy Co (NYSE: 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.